NCT06118866View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

PHASE2CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

August 26, 2024

Study Completion Date

November 28, 2024

Conditions
Androgenetic Alopecia
Interventions
DRUG

placebo-Q2W

placebo, 0mg，SC，Q2W，12 cycles

DRUG

HMI-115-120mg-Q4W

HMI-115, 120mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)

DRUG

HMI-115-240mg-Q4W

HMI-115, 240mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)

DRUG

HMI-115, 240mg-Q2W

HMI-115, 240mg，SC，Q2W，12 cycles

Trial Locations (1)

100035

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Hope Medicine (Nanjing) Co., Ltd

INDUSTRY

NCT06118866 - A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia | Biotech Hunter | Biotech Hunter